Talimogene laherparepvec Alternatives Compared
Talimogene laherparepvec | Ipilimumab | Opdivo |
|
---|
Talimogene laherparepvec | Ipilimumab | Opdivo (nivolumab) |
|
|||||||
---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Melanoma, Melanoma - Metastatic. talimogene laherparepvec may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Melanoma - Metastatic, Renal Cell Carcinoma, Malignant Pleural Mesothelioma, Melanoma, Colorectal Cancer. ipilimumab may also be used for purposes not listed in this medication guide. |
Prescription only
Opdivo is an immune checkpoint inhibitor that may be used to treat many different cancers including melanoma, bladder cancer, liver cancer, and lung cancer. Fatigue, skin conditions, a cough, upper... View more |
||||||||
More about Talimogene laherparepvec | More about Ipilimumab | More about Opdivo (nivolumab) | ||||||||
Ratings & Reviews | ||||||||||
Be the first to share your experience with this drug. |
Ipilimumab has an average rating of 7.0 out of 10 from a total of 4 ratings on Drugs.com. 50% of reviewers reported a positive effect, while 25% reported a negative effect. |
Opdivo has an average rating of 5.2 out of 10 from a total of 86 ratings on Drugs.com. 45% of reviewers reported a positive effect, while 47% reported a negative effect. |
||||||||
Drug Class | ||||||||||
Side Effects | ||||||||||
See also: talimogene laherparepvec side effects in more detail. |
See also: ipilimumab side effects in more detail. |
See also: Opdivo side effects in more detail. |
||||||||
Generic Availability | ||||||||||
N/A |
N/A |
N/A |
||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Opdivo prices |
||||||||
Dosage Forms Available | ||||||||||
N/A |
N/A |
|
||||||||
Brand Names | ||||||||||
Imlygic | Yervoy |
N/A |
||||||||
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||
N/A |
352.8 hours |
640.8 hours |
||||||||
CSA Schedule ** View glossary of terms | ||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
Pregnancy Category | ||||||||||
Summary unavailable. See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||
Drug Interactions | ||||||||||
A total of 274 drugs are known to interact with talimogene laherparepvec:
|
A total of 155 drugs are known to interact with ipilimumab:
|
A total of 16 drugs are known to interact with Opdivo:
|
||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||
Disease Interactions | ||||||||||
First Approval Date | ||||||||||
N/A |
N/A |
December 22, 2014 |
||||||||
WADA Class View World Anti-Doping Agency classifications. | ||||||||||
N/A |
N/A |
N/A |
||||||||
More Information | ||||||||||
Patient resources | ||||||||||
Professional Resources | ||||||||||
Related Treatment Guide | ||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.